StockData
UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31

UNITED THERAPEUTICS Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$543.15+10.03 (+1.88%)

Close on Oct 19, 2026

Market cap
$24.88B
P/E (TTM)
19.4
Dividend yield
–

United Therapeutics statistics

Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison

Valuation

MeasureUnited TherapeuticsIndustry median
Market Cap$23.30B$197.05M
Enterprise Value$20.63B$106.56M
PE Ratio19.4320.52
PS Ratio7.393.93
PB Ratio3.642.14
P/TBV Ratio3.642.46
P/FCF Ratio21.3118.25
P/OCF Ratio13.8213.78

Enterprise value

MeasureUnited TherapeuticsIndustry median
EV / Sales6.542.69
EV / EBITDA13.8214.86
EV / EBIT14.7219.00
EV / FCF18.8821.02

Income (trailing twelve months)

MeasureUnited TherapeuticsIndustry median
Revenue$3.15B$57.94M
Gross Profit$2.72B$90.47M
Operating Income$1.40B-$21.44M
Pretax Income$1.57B-$14.45M
Net Income$1.31B-$22.46M
EBITDA$1.49B-$16.91M
EPS (Diluted)$27.95-$0.83

Margins

MeasureUnited TherapeuticsIndustry median
Gross Margin86.1%52.3%
Operating Margin44.4%-44.5%
Pretax Margin49.9%-13.0%
Profit Margin41.6%-39.2%
EBITDA Margin47.3%-31.3%
FCF Margin34.6%-8.85%

Returns

MeasureUnited TherapeuticsIndustry median
Return on Equity (ROE)19.3%-53.1%
Return on Assets (ROA)17.3%-41.0%
Return on Invested Capital (ROIC)29.7%-32.0%
Return on Capital Employed (ROCE)21.2%-37.8%

Growth

MeasureUnited TherapeuticsIndustry median
Revenue Growth (YoY)2.49%6.01%
Net Income Growth (YoY)5.54%-37.7%
EPS Growth (YoY)9.01%-29.2%
FCF Growth (YoY)2.05%2.34%
Revenue Growth (3Y CAGR)18.0%2.25%
Revenue Growth (5Y CAGR)16.5%6.42%
EPS Growth (3Y CAGR)22.9%-0.17%
EPS Growth (5Y CAGR)19.3%3.77%

Balance sheet

MeasureUnited TherapeuticsIndustry median
Cash & Short-Term Investments$2.66B$62.42M
Net Cash (Debt)$2.66B$15.68M
Net Cash Per Share$62.07$0.65
Equity (Book Value)$6.40B$48.79M
Book Value Per Share$149.22$1.36
Tangible Book Value$6.40B$23.06M
Working Capital$2.88B$75.77M

Financial position

MeasureUnited TherapeuticsIndustry median
Current Ratio5.733.30
Quick Ratio4.892.39
Interest Coverage116.82-7.12

Cash flow (trailing twelve months)

MeasureUnited TherapeuticsIndustry median
Operating Cash Flow$1.69B-$12.35M
Capital Expenditures-$592.20M-$1.06M
Free Cash Flow$1.09B-$20.28M
FCF Per Share$25.48-$0.41

Efficiency

MeasureUnited TherapeuticsIndustry median
Asset Turnover0.420.38
Inventory Turnover2.412.67
Revenue Per Employee$2.25M$398.96K
Profits Per Employee$936.36K-$732.08K
Employee Count1,40073

Dividends and yields

MeasureUnited TherapeuticsIndustry median
Earnings Yield5.63%-21.2%
FCF Yield4.69%-7.64%
Buyback Yield10.7%-0.58%
Shareholder Yield10.7%0.00%

Shares

MeasureUnited TherapeuticsIndustry median
Shares Outstanding42,890,70059,128,900
Shares Change (YoY)-3.20%11.1%
Shares Change (QoQ)1.23%0.54%
Float40,361,70048,744,500
Shares Held by Insiders5.90%11.8%
Shares Held by Institutions97.4%59.4%

Taxes

MeasureUnited TherapeuticsIndustry median
Income Tax$262.10M$91.50K
Effective Tax Rate16.7%20.6%

Scores

MeasureUnited TherapeuticsIndustry median
Graham Number$306.34$17.36
Graham Upside-43.6%-45.5%
Altman Z-Score20.380.10
Piotroski F-Score84
Beneish M-Score-2.26-2.62

Calculated by StockData from United Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.